Tell me about radio pharmaceuticals
Radiopharmaceuticals for Prostate Cancer
Radiopharmaceuticals are special medications that combine radioactive material with compounds that target cancer cells. They're used both to find cancer (diagnostic imaging) and to treat it (therapeutic treatment). Let me explain how they work for prostate cancer.
How They Work
Radiopharmaceuticals use a "guided missile" approach—they're designed to seek out and attach to specific markers on prostate cancer cells, then deliver radiation directly to the tumor while minimizing damage to healthy tissue.
Key Radiopharmaceuticals for Prostate Cancer
For Imaging (Finding Cancer):
- PSMA PET imaging - Uses a radioactive tracer that binds to PSMA (prostate-specific membrane antigen), a protein found on prostate cancer cells. This helps doctors locate where cancer has spread.
For Treatment:
-
Lutetium-177 PSMA-617 (Pluvicto®) - FDA-approved in 2023 for advanced prostate cancer that has spread and no longer responds to hormone therapy. According to NCCN Guidelines for Prostate Cancer, this is now a recommended option for metastatic castration-resistant prostate cancer (mCRPC).
-
Radium-223 (Xofigo®) - Targets bone metastases (cancer spread to bones) and has been shown to extend survival in advanced disease.
What the Guidelines Say
The American Society of Clinical Oncology (ASCO) and NCCN now recognize PSMA-targeted radiopharmaceuticals as important treatment options, particularly for patients whose cancer has progressed despite other treatments.
Important Considerations
- These are typically used for advanced disease that has spread beyond the prostate
- Side effects can include fatigue, nausea, and bone marrow effects
- Treatment requires specialized nuclear medicine facilities
Have you been recommended one of these treatments, or are you exploring your options? I'm happy to discuss more specifics about what might apply to your situation.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Prostate Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated November 5, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Prostate Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with general for Prostate Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Prostate Cancer
- Tell me about prostate cancer stage t3
- Tell me about bipolar androgen therapy for Prostate cancer
- What does circulating tumor DNA (ctDNA) testing tell me about my Prostate Cancer
- In Brisbane how do I get it for my dad. Stage 3 prostate cancer 75 year old...
- Rising after prostatectomy. What are my options
- What is the best tool for diagnosing Neuro-Endocrine Prostate Cancer? Best regards. Alexander Lalov...
- A prostate measured at 180 and PSA 11.5. I am 76 and have no health problems and feel great. To be sure this week I...
- A prostate measured at 180 and PSA 11.5. I am 76 and have no health problems and feel great. I have no insurance and...